KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Tax Provisions (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Tax Provisions for 12 consecutive years, with $921000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 1379.17% year-over-year to $921000.0, compared with a TTM value of $988000.0 through Dec 2025, up 723.33%, and an annual FY2025 reading of $988000.0, up 723.33% over the prior year.
  • Tax Provisions was $921000.0 for Q4 2025 at Travere Therapeutics, up from $8000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $921000.0 in Q4 2025 and bottomed at -$84000.0 in Q3 2024.
  • Average Tax Provisions over 5 years is $102650.0, with a median of $52500.0 recorded in 2022.
  • The sharpest move saw Tax Provisions surged 1475.0% in 2022, then crashed 800.0% in 2024.
  • Year by year, Tax Provisions stood at $4000.0 in 2021, then soared by 1475.0% to $63000.0 in 2022, then increased by 7.94% to $68000.0 in 2023, then plummeted by 205.88% to -$72000.0 in 2024, then surged by 1379.17% to $921000.0 in 2025.
  • Business Quant data shows Tax Provisions for TVTX at $921000.0 in Q4 2025, $8000.0 in Q3 2025, and $20000.0 in Q2 2025.